alexa
Reach Us +44-1904-929220
Molecular Imaging As Biomarker Of Tumor Heterogeneity | 16488
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Molecular imaging as biomarker of tumor heterogeneity

5th International Conference on Biomarkers & Clinical Research

Gabriella Baio

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.021

Abstract
T he development of the new biological drugs in the treatment of cancer has recently renewed the concept of ?tumor heterogeneity?. The effects of the new targeted therapy, such as angiogenesis inhibitors and antivascular therapies, are more complex, compared to the well known cytotoxic drugs. The intra- and inter-tumor heterogeneity, heterogeneity between metastatic disease, and also heterogeneity that happens over time, profoundly influence the treatment outcome of patients. At present, tailored medicine heavily relies on the pathological characterization of tumor by biopsies but we should have multiple biopsies of the same tumor in the same patients, to study the dedifferentiation of a metastatic disease under treatment. Considering the invasive limitations and the issue of expression heterogeneity, molecular imaging, represent one of the most important and attractive challenge of Radiology. It allows non-invasive whole body characterization of in vivo tumor tissues by using multimodality imaging techniques (such as FDG-PET, non FDG-PET, DWI-MRI, Ultrasound targeted contrast Agents and Optical Imaging). All together, these techniques, offer a morphological and quantitative/functional imaging characterization, in a real time manner. They can be safely performed and repeated multiple times, providing information about heterogeneity in the primitive or metastatic disease. On the other hand, the future of molecular imaging is limited in terms of sensitivity, specificity and clinical translatability. The sensitivity is dependent on the molecular probes that are used and the specificity is dependent on the imaging signal obtained. Indeed, still few multimodality imaging techniques are applied in the clinical trials. In this view, we expect that the improvement of the technology behind molecular imaging, with a more availability and knowledge of the application of these techniques in the clinical settings, will definitely improve the diagnosis and the monitoring treatment in clinical cancer practice.
Biography
Gabriella Baio studied Medicine and Surgery at University of Pisa and she obtained Radiology specialization at University of Genoa in 2007. Since 2008, she works as Radiologist at IRCCS Azienda Ospedaliera Universitaria San Martino-IST-National Cancer Institute, in Genoa. Dott. Baio research activities, cover clinical and preclinical molecular imaging by Magnetic Resonance and Optical Imaging applied to oncology, vascular and neuroscience. Her current research consist in the characterization of breast cancer in animal model, in order to validate new contrast agents as potential biomarkers for early diagnosis and drug delivery. She is invited speaker to national and international conferences and an active member of the European Society of Molecular Imaging (ESMI). She has been abstract reviewer for the World Molecular Imaging Congress (WMIC) 2011 and 2012.
Relevant Topics
Top